A learned six-gene score associates with archived glioma survival
Source check: Source checked. Not independent scientific confirmation.
Finding: Random-forest and LASSO selection produced a six-gene score associated with overall survival in archived lower-grade glioma data. The source also reports survival separation in three additional datasets using each cohort’s own median cutoff. This does not establish a fixed clinical threshold, a causal tumor mechanism or benefit from a selected drug.
Technology: Random survival forest; LASSO
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Random forest and LASSO selected overlapping genes, followed by multivariable Cox scoring; the learned selection enables the represented expression-to-survival association.
- Test and result
- The source divided 497 TCGA cases into 348 development and 149 internal-validation records. Six genes remained after intersecting selectors and Cox refinement; survival comparisons were repeated in CGGA325, CGGA693 and GSE16011.
- Limitation / still unknown
- Prognostic screening before the split and reuse of the full TCGA cohort as Test2 limit independence. The three additional datasets used cohort-specific medians, so fixed-threshold validation is unestablished. Dataset overlap, endpoint harmonization and full preprocessing isolation were not independently reconstructed. Outcome-selected clusters are not newly verified biological subtypes; inferred immune activity and drug sensitivity are outside this result.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11402926/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary data/model-construction Methods and survival Results only; no operational laboratory procedures reviewed.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.